Clinical trials
ARDS (Moderate or Severe) clinical trials
Below are recruiting ards (moderate or severe) clinical trials, each written for real people, not researchers. We’re tracking 1,471 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05928039RecruitingPhase 4
Choosing the best first biologic for Crohn’s in the ileum
This Phase 4 trial tests which type of biologic medicine works best as the first treatment for people with moderate-to-severe Crohn’s that mainly affects the ileum. It may help you and your care team choose a more effective first option, based on which strategy leads to better control of symptoms and intestinal inflammation.
Calgary, AlbertaAges 18 years+ - NCT06962020Recruiting
Choosing the best first biologic for moderate to severe colitis
This study compares two first-line biologic drugs for moderate to severe ulcerative colitis to see which works better and why. The goal is to help find the best biologic treatment for each patient.
Shanxi, Xi'anAges 18–70 - NCT06313333Recruiting
National registry for moderate to severe adult atopic dermatitis
This registry tracks adults with moderate to severe atopic dermatitis (eczema) over time. It helps doctors learn more about the disease and how treatments work in real life.
Brescia, BresciaAges 18 years+ - NCT06946641RecruitingPhase 1
Testing QLS12010 safety in healthy adults and people with eczema
This trial tests a new drug, QLS12010, to see if it is safe and how it works in healthy volunteers and in people with moderate to severe atopic dermatitis (eczema). It may offer a new treatment option for those whose eczema has not improved with topical creams.
BeijingAges 18–75 - NCT06947980RecruitingPhase 2
Study of CM512 for moderate-to-severe atopic dermatitis
This trial tests a new treatment called CM512 for people with moderate-to-severe eczema (atopic dermatitis). It aims to see if the drug can improve skin symptoms like itching and rash.
BeijingAges 18–75 - NCT06947993RecruitingPhase 2
Study of a new treatment for moderate to severe eczema
This study tests an experimental treatment for people with moderate to severe eczema that has lasted at least a year. It aims to see if the new medicine can help control symptoms better than current options.
Birmingham, AlabamaAges 18–100 - NCT06937086RecruitingPhase 3
Mirikizumab plus tirzepatide for UC with obesity
This study tests whether adding mirikizumab to the weight-loss drug tirzepatide helps people with moderate-to-severe ulcerative colitis who also have obesity or overweight. It aims to see if the combination reduces bowel inflammation and helps with weight management.
Dothan, AlabamaAges 18–70 - NCT06934252RecruitingPhase 1
Study of TRB-061 for atopic dermatitis (eczema)
This trial tests an investigational drug called TRB-061 in healthy adults and people with atopic dermatitis (eczema). It aims to see if the drug is safe and how the body processes it. If you have moderate to severe eczema that started at least a year ago, you may be able to join the patient part of the study.
Belconnen, Australian Capital TerritoryAges 18–70 - NCT06937099RecruitingPhase 3
Testing two drugs for Crohn's with weight issues
This trial tests two study drugs, mirikizumab and tirzepatide, in people with moderate to severe Crohn's disease who also have overweight or obesity. The goal is to see if these treatments can help control Crohn's symptoms and inflammation.
Dothan, AlabamaAges 18–70 - NCT05896800Recruiting
Inhaled nitric oxide for moderate to severe COPD symptoms
This study tests whether inhaled nitric oxide gas can improve outcomes in people with moderate-to-severe chronic obstructive pulmonary disease (COPD). It may help reduce breathing problems by targeting how airways and blood vessels respond in the lungs.
Nanjing, JiangsuAges 40–75 - NCT06917742RecruitingPhase 1
Study of CPTX2309 for rheumatoid arthritis and lupus
This trial tests an investigational drug called CPTX2309, given intravenously, for people with moderate to severe rheumatoid arthritis or systemic lupus erythematosus. It aims to see if the drug is safe and effective.
Herston, QueenslandAges 18–65 - NCT06917651RecruitingPhase 3
Study of a new pain medicine for arm or leg injuries in the ER
This trial tests a fast-acting pain pill (sufentanil) placed under the tongue for people with moderate to severe pain from a single arm or leg injury. It aims to see if it works well in the emergency room.
FranceAges 18 years+ - NCT06903884RecruitingPhase 3
Diquafosol eye drops for moderate-to-severe eye allergy
This trial tests a new eye drop called diquafosol for people with a severe, active eye allergy called vernal keratoconjunctivitis. It aims to see if the drops can calm the allergy and help heal the surface of the eye.
Hong KongAges 6 years+ - NCT06899204Recruiting
Abrocitinib for atopic dermatitis after biologic therapy
This study looks at how well abrocitinib (a daily pill) works for people with moderate to severe eczema who have already tried biologic medicines and didn't get enough relief. It aims to see if this treatment can help you better manage your eczema.
San Diego, CaliforniaAges 12 years+ - NCT06888193RecruitingPhase 1
Bimekizumab in breast milk of mothers being treated
This study measures how much bimekizumab (Bimzelx) gets into breast milk. It helps us understand if the medicine is safe for breastfeeding babies whose mothers take this drug.
Santa Monica, CaliforniaAges 18 years+ - NCT06883305RecruitingPhase 3
Testing tezepelumab for moderate to severe COPD
This trial tests tezepelumab, an injected medication, for people with moderate to very severe COPD who still have flare-ups despite using standard inhalers. It may help reduce flare-ups and improve breathing for those with higher eosinophil levels.
Foley, AlabamaAges 40–80 - NCT06878261RecruitingPhase 3
Tezepelumab for moderate to very severe COPD
This study tests a new medication called tezepelumab (given as a shot) to see if it can reduce COPD flare-ups in people with moderate to very severe COPD who have had recent flare-ups despite using inhalers. It may be an option for those with higher levels of eosinophils (a type of white blood cell) in their blood.
Birmingham, AlabamaAges 40–80 - NCT06860659Enrolling by invitationPhase 4
Hyaluronate eye drops for moderate to severe dry eye
This trial tests whether 0.28% sodium hyaluronate eye drops can help people with moderate to severe dry eye feel better. It's for patients who have significant dry eye symptoms and signs on an eye exam.
Bangkok, BangkokAges 18 years+ - NCT06857942RecruitingPhase 4
Tirzepatide added to ixekizumab for psoriasis and weight issues
This trial tests whether adding tirzepatide (a weight-loss and diabetes drug) to ixekizumab (a psoriasis treatment) helps people with moderate-to-severe psoriasis who are overweight or have obesity. It is for those already taking ixekizumab for about 3 months.
Phoenix, ArizonaAges 18 years+ - NCT06062212Recruiting
Effects of lung pressure on recovery in severe ARDS on ECMO
This trial looks at how changes in lung pressure during breathing might affect recovery in patients with severe ARDS who are on a heart-lung bypass machine (ECMO). It could help doctors improve treatment for people with this serious lung condition.
Beijing, Beijing MunicipalityAges 18–75 - NCT06850727RecruitingPhase 2
Study of OD-07656 then vedolizumab for ulcerative colitis
This trial tests a new drug, OD-07656, followed by vedolizumab, in people with moderate to severe ulcerative colitis. It aims to see if this approach is safe and helps control symptoms when other treatments have not worked well.
BirtinyaAges 18–75 - NCT06854796Enrolling by invitation
Collagen gel for nose-to-mouth lines
This trial is testing a new collagen gel to reduce moderate to deep nose-to-mouth lines. It compares the gel to a control (no active treatment) to see if it works better and is safe.
BeijingAges 18–65 - NCT06838845Recruiting
A study on upadacitinib for Chinese adults with moderate to severe ulcerative colitis
This study is looking at how well the drug upadacitinib works and how safe it is for Chinese adults with moderate to severe ulcerative colitis. It is not a treatment trial, but will observe patients who are already taking upadacitinib as decided by their doctor.
Guangzhou, GuangdongAges 18 years+ - NCT06842199RecruitingPhase 3
Testing a new pill for moderate to severe plaque psoriasis
This trial tests an experimental drug called ICP-488 for people with moderate to severe plaque psoriasis. It aims to see if the drug can improve symptoms and is safe, and may be an option if you need stronger treatment than creams or light therapy.
Hefei, AnhuiAges 18–75
Hear when a new ARDS (Moderate or Severe) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for ards (moderate or severe)?
- Yes. Clin2 currently lists 1,471 recruiting ards (moderate or severe) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a ards (moderate or severe) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a ards (moderate or severe) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.